Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on AtheroNova Inc.
06 Junho 2012 - 3:00PM
Marketwired
Crystal Research Associates, LLC announced today that it has issued
an Executive Informational Overview® (EIO) on AtheroNova Inc.
(OTCBB: AHRO). The full 52-page report can be found at
www.crystalra.com.
AtheroNova Inc. ("AtheroNova" or "the Company") is a
development-stage biotechnology company targeting novel compounds
to dissolve or regress atherosclerotic plaque deposits -- a
thickening of the arteries due to buildup of fat, cholesterol, and
other substances. These plaque deposits, which progressively narrow
and block the arteries, are the main underlying cause of
cardiovascular disease, including heart attack, stroke, and
peripheral artery disease (PAD). The Company's most advanced
candidate, AHRO-001, works to significantly reduce the incidence
and severity of plaque by employing a bile salt to dissolve
existing atherosclerotic plaque deposits as well as prevent the
formation of new ones.
Bile salts are a U.S. Food and Drug Administration
(FDA)-approved natural compound used to dissolve gallstones.
Following a pre-Investigational New Drug (IND) meeting with the FDA
in October 2011, the Company is now preparing for AHRO-001 to enter
Phase I human clinical trials. Beyond development of AHRO-001,
AtheroNova expects to employ its intellectual property (IP) to
develop multiple pharmaceutical-grade applications for its
compounds, potentially in the areas of obesity, hypertension,
diabetes, PAD, localized transdermal fat dissolution, and the
non-invasive dissolution of lipomas.
Be the first to hear about Crystal Research's new report
releases and upcoming media coverage. Follow us on Twitter at
http://twitter.com/crystalresearch or visit
http://crystalra.com/blog/ to stay up-to-date on industry and
company news for clients under our research coverage.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm
that provides institutional-quality research on small- and mid-cap
companies. The firm is led by veteran Wall Street sell-side analyst
Jeffrey Kraws, who is well known by the international financial
media for his years of work on Wall Street and for providing
consistent award-winning analyses and developing long-term
relationships on both the buy-side and sell-side. He has been
consistently ranked on Wall Street among the Top Ten Analysts for
pharmaceutical stock performance in the world for almost two
decades as well as ranked as the Number One Stock Picker in the
world for pharmaceuticals by Starmine and for estimates from Zacks.
Additionally, Mr. Kraws has been 5-Star ranked for top
biotechnology stock performance by Starmine.
Crystal Research Associates' unique and novel product, the
Executive Informational Overview® (EIO), is free of investment
ratings, target prices, and forward-looking financial models. The
EIO presents a crystal clear, detailed report on a company (public
or private) in a manner that is easily understood by the Wall
Street financial community. The EIO details a company's
product/technology/service offerings, market size(s), key
intellectual property, leadership, growth strategy, competition,
risks, financial statements, key events, and other such fundamental
information. Crystal Research Associates has offices in New York
City, West Palm Beach, Montréal, and Toronto. Crystal Research
Associates' compensation by the Company for its first year of
service in creating this report and for updates is forty-two
thousand U.S. dollars and fifty thousand restricted shares.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and
operating results, potential applications of the Company's
technology, opportunities for the Company, and any other statements
about the future expectations, beliefs, goals, plans, or prospects
expressed constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words "will," "believes," "plans,"
"anticipates," "expects," "estimates," and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including limited operating history,
need for future capital, and economic conditions generally.
Additional information on potential factors that could affect
results and other risks and uncertainties are detailed from time to
time in the Company's periodic reports, including forms filed with
the SEC.
These statements, and other forward-looking statements, are not
guarantees of future performance and involve risks and
uncertainties. Crystal Research Associates assumes no obligation to
update any of the forward-looking statements in this release.
Contact: Jeffrey J. Kraws/Karen B. Goldfarb Crystal Research
Associates, LLC P: (609) 306-2274 F: (609) 395-9339
Authentic (CE) (USOTC:AHRO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Authentic (CE) (USOTC:AHRO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024